Roche kicks off Parkinson's collaboration with $30M milestone; Celladon will try again on IPO;

@FierceBiotech: U.K. to digitize patient health records and sell access to biopharma researchers. Story from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: U.K. group looks to ignite a Boston-style biotech comeback. More | Follow @JohnCFierce

@DamianFierce: Reminder that FierceBiotech's annual list of the most influential people in biopharma is now (somewhat) democratic. More | Follow @DamianFierce

@EmilyMFierce: This map of vaccine-preventable diseases is pretty striking. Map | Follow @EmilyMFierce

> Ireland's Prothena picked up a $30 million milestone payment from Roche with the launch of their collaboration on PRX002, an early-stage Parkinson's drug. Release

> Celladon has filed an amended S-1, reviving its plan to launch an IPO. Story

> The U.K.'s Prosonix announced positive top-line results from its Phase II clinical study with PSX1002 in patients with moderate to severe chronic obstructive pulmonary disease. Release

Medical Device News

@FierceMedDev: In 2013, eNeura won de novo approval in the U.S. for its anti-migraine device. Report | Follow @FierceMedDev

@MarkHFierce: Stryker grew net sales by 5.6% in Q4. Release | Follow @MarkHFierce

@MichaelGFierce: Statins delivered with HDL nanoparticles reduce risk of second heart attack, stroke. Story from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Quest Diagnostics inks $570M Solstas deal. Story | Follow @EmilyWFierce

> Covidien opens an Indian medical training center with a med tech focus. Article

> Varian touts emerging markets as looming Medicare changes take a toll. News

> Quest Diagnostics will pay $570M for another laboratory testing outfit. Item

> For Stryker, acquisitions began to generate financial benefits in late 2013. More

> Medtronic wins patent loss reversal in U.S. Supreme Court. Report

Pharma News

@FiercePharma: Biotechs trumpet pandemic vaccine deals and data as the H7N9 bird flu threat grows. Story from FierceVaccines | Follow @FiercePharma

@TracyStaton: Two top stories at FiercePharma yesterday are both RE Novartis job cuts. Swiss, with rehires (Story) and New York, with Novartis plant closing by 2017 (Story) | Follow @TracyStaton

@EricPFierce: Closing of US Lonza plant took a toll on its sales last quarter as expiring contracts were not renewed. Story from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: We're taking nominations for the 25 most influential people in biopharma for our annual report. Submit them here. Survey | Follow @CarlyHFierce

> Under investor pressure, Teva chairman pledges a smaller, more experienced board. Report

> With Iclusig back to market, would Eli Lilly bid for Ariad? Would anyone? Story

> Novo Nordisk quits South African pharma group over 'satanic' PR campaign. Article

Pharma Manufacturing News

> J&J consumer health boosts results, even without key plant. Story

> Par bolsters its sterile manufacturing with a $490M deal to grab JHP. Story

> New York plant that makes Diovan is next on Novartis' shutdown list. Story

> Glaxo is investing $200M in additions to its U.K. site. Story

> Lilly gets ready for track-and-trace in U.S. Item

> Lonza's pharma unit sales suffer as it closes U.S. biologics plant. Article

Vaccines News

> How vaccines helped India defeat polio while Pakistan became a reservoir for the virus. Story

> Study: Tightening vaccine exemption laws would cut cases of whooping cough. Story

> Map of vaccine-preventable diseases shows the scale of problems facing the West. Story

> Biotechs trumpet pandemic vaccine deals and data as the H7N9 bird flu threat grows. Story

> NIH backs New York MERS-CoV vaccine development program. Story

> The political causes of the Syrian polio crisis. Item

Suggested Articles

Novartis is picking up Vedere Bio and its preclinical gene therapies for $150 million upfront, with the promise of another $130 million.

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.